Bicycle Therapeutics PLC (BCYC) — 8-K Filings

8-K Filings (22)

• Bicycle Therapeutics Files 8-K Report — Apr 20, 2026 Risk: low
  On April 20, 2026, Bicycle Therapeutics plc filed an 8-K report detailing other events. The filing includes financial statements and exhibits, with specific XBR
• Bicycle Therapeutics Announces Executive Changes and Board Appointments — Sep 8, 2025 Risk: medium
  On September 8, 2025, Bicycle Therapeutics plc filed an 8-K report detailing the departure of Dr. Robert T. Drake as Chief Medical Officer and the appointment o
• Gilead to Acquire Bicycle Therapeutics for $1.5B — Aug 8, 2025 Risk: medium
  Bicycle Therapeutics plc announced on August 6, 2025, that it has entered into a definitive agreement to be acquired by a subsidiary of Gilead Sciences, Inc. fo
• Bicycle Therapeutics Files 8-K on Security Holder Vote — Jun 17, 2025 Risk: low
  On June 17, 2025, Bicycle Therapeutics plc filed an 8-K report indicating a submission of matters to a vote of security holders. The filing does not contain spe
• Bicycle Therapeutics Files 8-K Report — May 1, 2025 Risk: low
  On May 1, 2025, Bicycle Therapeutics plc filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, along w
• Bicycle Therapeutics Files 8-K Report — Apr 29, 2025 Risk: low
  On April 29, 2025, Bicycle Therapeutics plc filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate d
• Bicycle Therapeutics Announces Director Changes and Compensation Updates — Mar 27, 2025 Risk: low
  On March 21, 2025, Bicycle Therapeutics plc filed an 8-K report detailing several key events. These include the departure of director Dr. Jonathan M. Rothberg,
• Bicycle Therapeutics Files 8-K on Shareholder Nominations — Mar 14, 2025 Risk: medium
  Bicycle Therapeutics plc filed an 8-K on March 14, 2025, reporting shareholder nominations pursuant to Exchange Act Rule 14a-11 as of March 12, 2025. The filing
• Bicycle Therapeutics Files 8-K on Financials — Feb 25, 2025 Risk: low
  On February 25, 2025, Bicycle Therapeutics plc filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, a
• Bicycle Therapeutics Files 8-K Report — Jan 13, 2025 Risk: low
  On January 13, 2025, Bicycle Therapeutics plc filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and
• Bicycle Therapeutics Files 8-K — Dec 13, 2024 Risk: low
  On December 13, 2024, Bicycle Therapeutics plc filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with n
• Bicycle Therapeutics plc Files 8-K Report — Oct 31, 2024 Risk: low
  On October 31, 2024, Bicycle Therapeutics plc filed an 8-K report detailing its financial results and operations. The filing includes financial statements and e
• Bicycle Therapeutics Files 8-K Report — Oct 23, 2024 Risk: low
  On October 23, 2024, Bicycle Therapeutics plc filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicat
• Bicycle Therapeutics Files 8-K Report — Sep 19, 2024 Risk: low
  On September 14, 2024, Bicycle Therapeutics plc filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material
• Bicycle Therapeutics Files 8-K on Financials — Aug 6, 2024 Risk: low
  On August 6, 2024, Bicycle Therapeutics plc filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as w
• Bicycle Therapeutics Terminates Material Definitive Agreement — Jul 10, 2024 Risk: medium
  Bicycle Therapeutics plc announced on July 9, 2024, the termination of a material definitive agreement. The company, incorporated in England and Wales, filed th
• Bicycle Therapeutics Files 8-K Report — Jun 18, 2024 Risk: low
  On June 18, 2024, Bicycle Therapeutics plc filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating
• Bicycle Therapeutics Announces Material Definitive Agreement — May 23, 2024 Risk: medium
  Bicycle Therapeutics plc announced on May 23, 2024, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equit
• Bicycle Therapeutics Files 8-K on Security Holder Vote Matters — May 16, 2024 Risk: low
  On May 16, 2024, Bicycle Therapeutics plc filed an 8-K report indicating a submission of matters to a vote of security holders. The company, incorporated in Eng
• Bicycle Therapeutics Files 8-K on Financials — May 2, 2024 Risk: low
  Bicycle Therapeutics plc filed an 8-K on May 2, 2024, reporting on its results of operations and financial condition. The filing includes financial statements a
• Bicycle Therapeutics Reports Material Agreement and Officer Changes — Apr 18, 2024 Risk: medium
  On April 16, 2024, Bicycle Therapeutics plc entered into a material definitive agreement. The company also reported the departure of directors or certain office
• Bicycle Therapeutics Files 8-K on Operations, Officer Changes — Feb 20, 2024 Risk: low
  Bicycle Therapeutics plc filed an 8-K on February 20, 2024, reporting on its financial condition and operations. The filing also addressed the departure or appo

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX